Skip to main content

Table 2 The rate of patients’ annual use of each of the direct medical costs items and the unit price of each of them in 2019-2020

From: Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Cost components

natalizumab

rituximab

Count

Unit Price (PPP $)

Count

Unit Price (PPP $)

Physicians’ Visits

6

44

2

44

Main Medicines

12

2745

2

1019

Complete Blood Counts

2

30

2

30

Biochemistry Tests

2

30

2

30

Urinalysis Tests with Microscopy

–

–

2

25

Tuberculin Skin Test

–

–

1

25

JC Virus Test

2

73

–

–

Serology (HIV, HBV and HCV) Test

–

–

1

25

Magnetic Resonance Imaging (MRI)

1

500

3

500

Physiotherapy & Other Services Costs

They vary based on the patients’ conditions

Hospitalization

They vary based on the patients’ conditions

Supplementary Medicines

They vary based on the patients’ conditions